Assembly Biosciences ( NASDAQ: ASMB ) closed the issuance of shares of its common stock and warrants to Armistice Capital LLC, a healthcare-focused institutional investor, and Gilead Sciences, in separate equity financings that have resulted in aggregate gross proceeds to Assembly Bio of approximately $12.6 million. The sale of common stock to Gilead maintains Gilead’s ownership of 19.
9% of voting stock of Assembly Bio. Source: Press Release More on Assembly Biosciences Assembly Biosciences GAAP EPS of -$13.38 beats by $0.
90 Seeking Alpha’s Quant Rating on Assembly Biosciences Historical earnings data for Assembly Biosciences Financial information for Assembly Biosciences.
